About Human Longevity
Human Longevity is a company based in San Diego (United States) founded in 2013 by J Craig Venter and Peter H Diamandis. Human Longevity has raised $408.72 million across 6 funding rounds from investors including Illumina, General Electric and Synthetic Genomics. Human Longevity has completed 3 acquisitions, including Cypher Genomics, DoctorsForMe.AI and LifebankUSA. Human Longevity operates in a competitive market with competitors including Genomenon, IDbyDNA, Sequentia biotech, Gene Logic and Advaita Bioinformatics, among others.
- Headquarter San Diego, United States
- Founders J Craig Venter, Peter H Diamandis
-
Sectors
Technology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$408.72 M (USD)
in 6 rounds
-
Latest Funding Round
$39.8 M (USD), Series B
Aug 22, 2024
-
Investors
Illumina
& 10 more
-
Employee Count
Not available
-
Investments & Acquisitions
Cypher Genomics
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Human Longevity
Unlock access to complete
Funding Insights of Human Longevity
Human Longevity has successfully raised a total of $408.72M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $39.8 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Human Longevity
Human Longevity has secured backing from 11 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Illumina, General Electric and Synthetic Genomics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare growth capital investments are made in transformational companies.
|
Locked | Locked | Locked | |
|
A life sciences venture fund is operated with global reach.
|
Locked | Locked | Locked | |
|
Capital is provided to support biomedical industry innovations.
|
Locked | Locked | Locked |
Investor details for Human Longevity
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Human Longevity
Human Longevity has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Cypher Genomics, DoctorsForMe.AI and LifebankUSA.
Investment portfolio details for Human Longevity
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cancer patients are matched with expert doctors via AI platform.
|
Locked | Locked | 2018 | Locked | |
|
Cypher Genomics is engaged in genomic diagnostic solutions development.
|
Locked | Locked | 2011 | Locked | |
|
Full-service stem cell and cord blood storage services are offered.
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for Human Longevity
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Human Longevity
Detailed financials for Human Longevity
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Human Longevity Comparisons
Peer comparison for Human Longevity
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Human Longevity
Human Longevity operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Genomenon, IDbyDNA, Sequentia biotech, Gene Logic and Advaita Bioinformatics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based bioinformatics tools and genomic variants meta-database are developed.
|
|
| Locked | Locked | Locked |
Developer of search engine to identify pathogens in sample
|
|
| Locked | Locked | Locked |
Bioinformatics technologies and services are provided by the company.
|
|
| Locked | Locked | Locked |
Genomic reference databases and compliant microarray services are provided.
|
|
| Locked | Locked | Locked |
Bioinformatics software tools for multi-omics pathway analysis are provided.
|
Detailed competitors of Human Longevity
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Human Longevity
Complete news archive for Human Longevity
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Human Longevity
Human Longevity was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Human Longevity is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
J Craig Venter is the current CEO of Human Longevity. They have also founded this company.
Human Longevity is a funded company, having raised a total of $408.72M across 6 funding rounds to date.
Genomics data and cell therapy-based diagnostic and therapeutic solutions. It offers an AI-interfaced platform, enabling a genomics-based technology company to create a database of the whole genome, phenotype, and clinical data. It provides genome sequencing, analysis, and collaboration services for cell therapies and personalized vaccine development. It also offers support services for preventive and personalized care, including cancer analysis, integrated health analysis, newborn screening, and rare, undiagnosed diseases.
Human Longevity's top competitors include Genomenon, Sequentia biotech and Gene Logic.
Human Longevity has made 3 acquisitions, including Cypher Genomics, DoctorsForMe.AI, and LifebankUSA.
Human Longevity has 11 investors. Key investors include Illumina, General Electric, Synthetic Genomics, Celgene, and TVM Capital Healthcare.